AP2014007413A0 - Stable dosage forms of arterolane and piperaquine - Google Patents

Stable dosage forms of arterolane and piperaquine

Info

Publication number
AP2014007413A0
AP2014007413A0 AP2014007413A AP2014007413A AP2014007413A0 AP 2014007413 A0 AP2014007413 A0 AP 2014007413A0 AP 2014007413 A AP2014007413 A AP 2014007413A AP 2014007413 A AP2014007413 A AP 2014007413A AP 2014007413 A0 AP2014007413 A0 AP 2014007413A0
Authority
AP
ARIPO
Prior art keywords
arterolane
piperaquine
dosage forms
stable dosage
stable
Prior art date
Application number
AP2014007413A
Other languages
English (en)
Other versions
AP3777A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
Sumit Madan
Arno Appavoo Enose
Harish Kumar Madan
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/183,119 external-priority patent/US8664265B2/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of AP2014007413A0 publication Critical patent/AP2014007413A0/xx
Application granted granted Critical
Publication of AP3777A publication Critical patent/AP3777A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AP2014007413A 2011-07-14 2012-07-13 Stable dosage forms of arterolane and piperaquine AP2014007413A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/183,119 US8664265B2 (en) 2005-05-18 2011-07-14 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
IN2703DE2011 2011-09-19
IN2156DE2012 2012-07-12
PCT/IB2012/053614 WO2013008218A1 (en) 2011-07-14 2012-07-13 Stable dosage forms of arterolane and piperaquine

Publications (2)

Publication Number Publication Date
AP2014007413A0 true AP2014007413A0 (en) 2014-02-28
AP3777A AP3777A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-08-31

Family

ID=47505579

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007413A AP2014007413A0 (en) 2011-07-14 2012-07-13 Stable dosage forms of arterolane and piperaquine

Country Status (10)

Country Link
EP (1) EP2731603A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2014522856A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20140053169A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103930107A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2014007413A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012282077A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2850089A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201490233A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2014000463A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013008218A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014132226A1 (en) 2013-02-28 2014-09-04 Ranbaxy Laboratories Limited Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof
KR101698003B1 (ko) * 2016-06-20 2017-01-19 여오영 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
MX2020006055A (es) * 2017-12-12 2020-08-20 Intervet Int Bv Composiciones farmaceuticas implantables de isoxazolina y usos de las mismas.
TW202220645A (zh) * 2020-08-14 2022-06-01 印度商太陽製藥工業有限公司 用於治療瘧疾的固定劑量組合藥物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486199B1 (en) 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US6906205B2 (en) 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
EP1898901B1 (en) * 2005-05-18 2016-11-23 Sun Pharmaceutical Industries Limited Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
WO2007132438A2 (en) * 2006-05-17 2007-11-22 Ranbaxy Laboratories Limited Antimalarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative

Also Published As

Publication number Publication date
CN103930107A (zh) 2014-07-16
KR20140053169A (ko) 2014-05-07
EP2731603A1 (en) 2014-05-21
MX2014000463A (es) 2014-07-09
AP3777A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-08-31
EA201490233A1 (ru) 2014-07-30
AU2012282077A1 (en) 2014-01-30
CA2850089A1 (en) 2013-01-17
JP2014522856A (ja) 2014-09-08
EA201490233A8 (ru) 2015-01-30
WO2013008218A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
EP2776837A4 (en) COMBINATION OF KINASEINHIBITORS AND THEIR USE
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
SG11201406948PA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
IL232055B (en) Anti-1htra antibodies and methods of use
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2734513A4 (en) INTERMEDIATE PRODUCT OF STATIN MEDICINES AND THEIR MANUFACTURE
AP2014007413A0 (en) Stable dosage forms of arterolane and piperaquine
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
ZA201307230B (en) Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma-glutamyl-l-tryptophan
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
ZA201405276B (en) Stable dosage forms of arterolane and piperaquine
GB201104632D0 (en) Use of medicament
GB201112081D0 (en) Prodrugs of non-opioids and uses thereof
GB201111377D0 (en) Prodrugs of non-opioids and uses thereof
GB201112578D0 (en) Pharmaceutical preparation and use